Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2016 Aug 27

PMID 27562873

Citations 27

Authors

Kimberly K Scarsi

Kristin M Darin

Catherine A Chappell

Stephanie M Nitz

Mohammed Lamorde

Affiliations

Soon will be listed here.

Abstract

Family planning options, including hormonal contraceptives, are essential for improving reproductive health among the more than 17 million women living with HIV worldwide. For these women, prevention of unintended pregnancy decreases maternal and child mortality, as well as reduces the risk of perinatal HIV transmission. Similarly, treatment of HIV with antiretroviral therapy (ART) is essential for reducing morbidity and mortality among HIV-positive individuals, as well as preventing HIV transmission between sexual partners or from mother to child. Importantly, despite the benefits of hormonal contraceptives, barriers to effective family planning methods exist for HIV-positive women. Specifically, drug-drug interactions can occur between some antiretroviral medications and some hormonal contraceptives, which may influence both contraceptive efficacy and tolerability. In addition, safety concerns have been raised about the impact of hormonal contraceptives on HIV disease progression, tolerability, and the risk of female-to-male HIV transmission. This review article summarizes the potential for drug-drug interactions, tolerability, and contraceptive effectiveness when hormonal contraceptives are combined with ART. In addition, the evidence surrounding the influence of hormonal contraceptives on HIV transmission and HIV disease progression in women living with HIV are summarized.

Citing Articles

Nicotine is an Immunosuppressant: Implications for Women's Health and Disease.

White A, Craig A, Richie D, Corley C, Sadek S, Barton H J Neuroimmunol. 2024; 397:578468.

PMID: 39461120 PMC: 11653054. DOI: 10.1016/j.jneuroim.2024.578468.

Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.

Henderson A, Cholli P, Lampe M, Kourtis A Expert Rev Anti Infect Ther. 2024; 22(4):153-167.

PMID: 38517686 PMC: 11287786. DOI: 10.1080/14787210.2024.2334054.

Contraception and Abortion Care for People Living With HIV: A Clinical Guide for Reproductive Health Practitioners.

Yang L, Allen R, Cambou M, Nielsen-Saines K, Brown B J Midwifery Womens Health. 2023; 68(6):719-727.

PMID: 37903728 PMC: 10872909. DOI: 10.1111/jmwh.13575.

Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study.

Loutfy M, Lacombe-Duncan A, Tseng A, Persad Y, Underhill A, Kennedy V J Antimicrob Chemother. 2023; 78(11):2653-2659.

PMID: 37681452 PMC: 10631824. DOI: 10.1093/jac/dkad270.

Measuring the impact of COVID-19 social distancing measures on sexual health behaviours and access to HIV and sexual and reproductive health services for people living with HIV in Botswana.

Ensor S, Mechie I, Ryan R, Mussa A, Bame B, Tamuthiba L Front Glob Womens Health. 2023; 4:981478.

PMID: 36970120 PMC: 10030995. DOI: 10.3389/fgwh.2023.981478.

References

Balogh A, Gessinger S, Svarovsky U, Hippius M, Mellinger U, Klinger G . Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans?. Eur J Clin Pharmacol. 1999; 54(9-10):729-34. DOI: 10.1007/s002280050543. View

Anderson M, Hanley W, Moreau A, Jin B, Bieberdorf F, Kost J . Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol. 2011; 71(4):616-20. PMC: 3080652. DOI: 10.1111/j.1365-2125.2010.03885.x. View

Quinn T, Wawer M, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F . Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342(13):921-9. DOI: 10.1056/NEJM200003303421303. View

Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T . The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011; 16(2):157-64. DOI: 10.3851/IMP1724. View

Lehtovirta P, Paavonen J, Heikinheimo O . Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. Contraception. 2006; 75(1):37-9. DOI: 10.1016/j.contraception.2006.09.006. View

Day S, Graham S, Masese L, Richardson B, Kiarie J, Jaoko W . A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy. J Acquir Immune Defic Syndr. 2014; 66(4):452-6. PMC: 4419746. DOI: 10.1097/QAI.0000000000000187. View

. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep. 2012; 61(24):449-52. View

Vogler M, Patterson K, Kamemoto L, Park J, Watts H, Aweeka F . Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010; 55(4):473-82. PMC: 4197050. DOI: 10.1097/QAI.0b013e3181eb5ff5. View

Zhang H, Cui D, Wang B, Han Y, Balimane P, Yang Z . Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007; 46(2):133-57. DOI: 10.2165/00003088-200746020-00003. View

10.

Tjernlund A, Carias A, Andersson S, Gustafsson-Sanchez S, Rohl M, Petersson P . Progesterone-based intrauterine device use is associated with a thinner apical layer of the human ectocervical epithelium and a lower ZO-1 mRNA expression. Biol Reprod. 2015; 92(3):68. PMC: 4358022. DOI: 10.1095/biolreprod.114.122887. View

11.

Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K . Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003; 74(4):326-33. DOI: 10.1016/S0009-9236(03)00202-9. View

12.

Back D, Houlgrave R, Tjia J, Ward S, Orme M . Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol. 1991; 38(2):219-25. DOI: 10.1016/0960-0760(91)90129-s. View

13.

Benowitz N, Lessov-Schlaggar C, Swan G, Jacob 3rd P . Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006; 79(5):480-8. DOI: 10.1016/j.clpt.2006.01.008. View

14.

Baeten J, Kahle E, Lingappa J, Coombs R, Delany-Moretlwe S, Nakku-Joloba E . Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011; 3(77):77ra29. PMC: 3087186. DOI: 10.1126/scitranslmed.3001888. View

15.

Wang B, Sanchez R, Franklin R, Evans D, Huskey S . The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004; 32(11):1209-12. DOI: 10.1124/dmd.104.000182. View

16.

Lutalo T, Musoke R, Kong X, Makumbi F, Serwadda D, Nalugoda F . Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS. 2013; 27 Suppl 1:S27-34. DOI: 10.1097/QAD.0000000000000045. View

17.

Graham S, Masese L, Gitau R, Jalalian-Lechak Z, Richardson B, Peshu N . Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis. 2010; 202(10):1538-42. PMC: 2957525. DOI: 10.1086/656790. View

18.

Tsunoda S, Harris R, Mroczkowski P, Benet L . Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol. 2001; 38(12):1137-43. View

19.

Browne H, Manipalviratn S, Armstrong A . Using an intrauterine device in immunocompromised women. Obstet Gynecol. 2008; 112(3):667-9. PMC: 2607525. DOI: 10.1097/AOG.0b013e318183464e. View

20.

Mauck C, Callahan M, Baker J, Arbogast K, Veazey R, Stock R . The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception. 1999; 60(1):15-24. DOI: 10.1016/s0010-7824(99)00058-x. View